Last Updated: November 16, 2026

Investigational Drug Information for Eplivanserin

« Back to Dashboard


What is the development status for investigational drug Eplivanserin?

Eplivanserin is an investigational drug.

There have been 7 clinical trials for Eplivanserin. The most recent clinical trial was a Phase 3 trial, which was initiated on November 1st 2005.

The most common disease conditions in clinical trials are Sleep Initiation and Maintenance Disorders, Parasomnias, and Myofascial Pain Syndromes. The leading clinical trial sponsors are Sanofi and [disabled in preview].

Recent Clinical Trials for Eplivanserin
TitleSponsorPhase
Single Dose Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Evaluation of Eplivanserin in Children With InsomniaSanofiPhase 1
Efficacy and Safety of Eplivanserin 5mg/Day in Insomnia Characterized by Sleep Maintenance DifficultiesSanofiPhase 3
Comparison of Eplivanserin and Lormetazepam in the Treatment of Insomnia Characterized by Sleep Maintenance DifficultiesSanofiPhase 3

See all Eplivanserin clinical trials

Clinical Trial Summary for Eplivanserin

Top disease conditions for Eplivanserin
Top clinical trial sponsors for Eplivanserin

See all Eplivanserin clinical trials

Eplivanserin Development Update, Patent Status, FDA History, and Market Projection

Last updated: September 14, 2026

Eplivanserin is a discontinued investigational insomnia drug that targeted the serotonin 5-HT2A receptor. Sanofi-Aventis advanced the compound into late-stage development, but the U.S. program ended after the FDA raised efficacy and safety concerns in 2009. Eplivanserin has no FDA approval, no Orange Book listing, no commercial sales, and no established generic or biosimilar entry pathway. The base-case market projection is therefore zero revenue unless a sponsor restarts development and generates new clinical evidence.

What is eplivanserin and how was it supposed to work?

Eplivanserin is an oral, selective 5-HT2A receptor antagonist developed for insomnia. The proposed mechanism was intended to improve sleep maintenance and reduce nighttime awakenings without directly stimulating GABA-A receptors, the mechanism used by many older hypnotics.

Attribute Eplivanserin profile
Active ingredient Eplivanserin
Therapeutic area Insomnia and sleep-maintenance disorders
Drug class Selective serotonin 5-HT2A antagonist
Dosage form Oral investigational drug
Primary developer Sanofi-Aventis
Regulatory status Not approved
U.S. commercial status No launch
Orange Book status No approved product listing
Biosimilar relevance Not applicable
Current development status Discontinued or inactive

The development thesis was that selective 5-HT2A blockade could improve sleep architecture while avoiding some adverse effects associated with benzodiazepines and nonbenzodiazepine hypnotics. The clinical program did not establish a sufficient benefit-risk profile for approval.

What happened to eplivanserin development?

Sanofi-Aventis submitted eplivanserin for U.S. regulatory review after conducting Phase 3 studies in patients with insomnia. The FDA convened an advisory committee in September 2009 to review the application. The committee did not support approval based on concerns that the efficacy data were insufficient and that safety findings, including next-day effects, required further consideration. [1]

Sanofi subsequently withdrew the U.S. application. The company did not proceed to commercial launch, and eplivanserin did not become an approved insomnia treatment in the United States or a marketed product in major regulated markets.

Eplivanserin development timeline

Period Development event
Pre-2009 Sanofi-Aventis conducted clinical development in insomnia
2009 U.S. regulatory review and FDA advisory committee discussion
September 2009 FDA advisory committee reviewed the application and raised material efficacy and safety concerns
Late 2009 Sanofi withdrew the U.S. application
2010 onward No substantive commercial development or approved launch
Current status No active marketed product or publicly established late-stage program

The withdrawal removed the immediate regulatory path. A future sponsor would need to reassess the clinical package, establish a new development strategy, and likely conduct additional controlled trials.

What is the FDA regulatory status of eplivanserin?

Eplivanserin is not FDA-approved. It does not have an approved U.S. prescribing label, an established FDA-recognized indication, or an active commercial application leading to market authorization.

The FDA’s review focused on whether the drug produced a clinically meaningful improvement in insomnia outcomes and whether safety risks were acceptable. The regulatory issue was not simply manufacturing or chemistry. The central barrier was the benefit-risk profile demonstrated in clinical studies. [1]

Is eplivanserin in the Orange Book?

No approved eplivanserin drug product is listed in the FDA Orange Book. Because there is no approved reference product, there is no conventional abbreviated new drug application pathway based on an eplivanserin reference product. [2]

This distinction matters for generic-entry analysis. A company cannot launch an ordinary ANDA against an eplivanserin reference product because no such approved reference drug exists. A future development program would need to pursue a new drug application or another applicable regulatory route rather than rely on a standard generic substitution strategy.

What patents protect eplivanserin?

Publicly available regulatory and commercial records do not establish a current, commercially relevant patent estate for eplivanserin. Historical compound, formulation, and use patents may have been filed during the Sanofi development program, but the absence of an approved product means that patent protection did not translate into marketed exclusivity.

A definitive current patent assessment would require a family-level review of national records, including ownership changes, terminal disclaimers, maintenance fees, continuations, reexaminations, and expiration calculations. No active Orange Book-listed patent protection is associated with an approved eplivanserin product.

What formulations were protected by eplivanserin patents?

No approved eplivanserin formulation is listed in the Orange Book. Historical development likely involved conventional oral dosage forms, but the public regulatory record does not establish a commercially relevant formulation patent that currently blocks competing development.

Potential patent categories would include:

  • The eplivanserin chemical entity
  • Polymorphs, salts, or crystalline forms
  • Oral tablets or solid dosage compositions
  • Treatment of insomnia or sleep-maintenance disorders
  • Dosing regimens and patient-selection methods
  • Manufacturing processes and intermediates

Those categories should not be treated as equivalent to enforceable market exclusivity. Patent rights can expire independently of regulatory exclusivity, and a patent covering an investigational compound does not create a barrier to alternative insomnia therapies.

When did eplivanserin lose exclusivity?

Eplivanserin did not lose market exclusivity in the conventional sense because it never obtained U.S. approval or commercial launch. The relevant commercial event was the failure and withdrawal of the regulatory application, not generic erosion after a marketed period.

No FDA new chemical entity exclusivity period was granted for eplivanserin. No U.S. pediatric exclusivity period, orphan-drug exclusivity period, or approved-product regulatory exclusivity is identified.

How strong is the eplivanserin patent estate?

The commercial strength of the eplivanserin estate is low for three reasons:

  1. No approved product creates no Orange Book patent linkage.
  2. The regulatory failure limits the value of any remaining composition or method patents.
  3. Competing insomnia therapies use different mechanisms and do not need to practice eplivanserin claims.

Patent strength and asset value are separate questions. A technically valid historical patent could still have little commercial value if the underlying product cannot obtain approval or compete clinically.

Were there Paragraph IV challenges or patent litigation?

No material public Paragraph IV challenge or major patent litigation involving an approved eplivanserin product is established. That outcome is consistent with the absence of an approved reference drug and the withdrawal of the U.S. application.

There is also no established settlement agreement between Sanofi and a generic manufacturer tied to eplivanserin. Generic litigation generally becomes commercially relevant when an approved product has meaningful sales and listed patents. Eplivanserin did not reach that stage.

Are there licensing deals involving eplivanserin?

Sanofi-Aventis was the principal public developer associated with eplivanserin. No current licensing transaction, acquisition, or commercialization agreement has established an active development program for the compound.

The absence of a visible licensing deal reduces the likelihood of near-term reactivation. A restart would require a sponsor to acquire or confirm rights to the compound, review historical clinical and regulatory data, and determine whether new intellectual property could be generated around an improved formulation, patient population, or dosing regimen.

What is the competitive landscape for insomnia drugs?

Eplivanserin would enter a crowded market with multiple generic and branded mechanisms. The competitive environment has changed materially since the 2009 regulatory review.

Competitive category Examples Commercial implication
Nonbenzodiazepine hypnotics Zolpidem, zaleplon, eszopiclone Low-cost generic competition
Orexin receptor antagonists Suvorexant, lemborexant, daridorexant Branded alternatives with differentiated mechanisms
Melatonin-pathway drugs Ramelteon and generic melatonin products Compete in sleep-initiation and circadian indications
Sedating antidepressants and antipsychotics Off-label use Broadens treatment alternatives but raises safety and reimbursement issues
Serotonergic investigational agents Various pipeline compounds Potentially competing mechanism-based innovation

The current commercial opportunity is more difficult than it was when eplivanserin entered development. Generic prices constrain the lower end of the market, while orexin antagonists occupy the premium branded segment with established regulatory positioning.

How does eplivanserin compare with orexin antagonists?

Eplivanserin and orexin antagonists pursue different biological targets. Eplivanserin blocks 5-HT2A signaling, while orexin drugs inhibit wake-promoting orexin receptors. Orexin antagonists have secured regulatory approvals and commercial distribution, giving them a substantial development and market-access advantage.

Eplivanserin would need evidence of a clinically meaningful benefit over existing generic hypnotics and newer branded agents. A mechanistic distinction alone would not support premium pricing.

What is the market projection for eplivanserin?

The base-case projection is zero commercial revenue from 2025 onward because eplivanserin has no approved product, no active public development program, and no identified launch plan.

Scenario Probability assessment Revenue outlook
Base case: no restart Most supportable scenario Zero product revenue
Academic or exploratory restart Limited commercial impact No near-term revenue
Full clinical redevelopment Requires new trials and financing No revenue before regulatory approval
Successful relaunch Low-confidence upside case Potential branded insomnia revenue, but unquantifiable from public data

A relaunch would require at least:

  • A sponsor with secured global rights
  • Updated pharmacology and toxicology review
  • New or confirmatory Phase 2 and Phase 3 studies
  • A clear insomnia population and endpoint strategy
  • FDA agreement on the development plan
  • A commercial positioning strategy against orexin antagonists and generic hypnotics

The commercial ceiling would depend on whether eplivanserin could demonstrate a differentiated profile in sleep maintenance, next-day functioning, abuse liability, or tolerability. The historical FDA concerns make this a high-risk redevelopment project.

What revenue exposure exists for Sanofi?

No current revenue exposure from eplivanserin is apparent because the drug was not launched. The compound does not appear to be a material contributor to Sanofi’s current pharmaceutical sales base.

Any valuation assigned to eplivanserin would be option value rather than forecast product revenue. That value would depend on enforceable rights, surviving patent protection, clinical data ownership, and the feasibility of obtaining a new regulatory approval.

Is there biosimilar risk for eplivanserin?

No. Biosimilars apply to biologic products, whereas eplivanserin is a synthetic small molecule. The relevant competitive risks would be generic small-molecule development, alternative insomnia drugs, and branded products with stronger regulatory and reimbursement positions.

Because eplivanserin was never approved, standard generic substitution risk is also not currently active. The larger risk is that alternative products satisfy the same clinical need without infringing any eplivanserin patent claims.

Key Takeaways

  • Eplivanserin is a discontinued investigational 5-HT2A antagonist for insomnia.
  • Sanofi-Aventis withdrew the U.S. application after FDA review raised efficacy and safety concerns.
  • The drug has no FDA approval, no Orange Book listing, and no commercial sales.
  • No active Paragraph IV dispute, major patent litigation, or current licensing transaction is established.
  • Historical patents may exist, but no current commercial exclusivity position is apparent.
  • Biosimilar risk is irrelevant because eplivanserin is a small molecule.
  • The base-case 2025-2030 market projection is zero revenue.
  • Any upside depends on a full redevelopment program, new clinical evidence, and a viable commercial position against generic hypnotics and orexin antagonists.

FAQs About Eplivanserin

Is eplivanserin still being developed?

No active late-stage or commercial development program is publicly established. The original Sanofi-Aventis program ended after the U.S. regulatory setback.

Did the FDA approve eplivanserin?

No. Eplivanserin did not receive FDA approval and has no U.S. prescribing information.

Can a generic company file an ANDA for eplivanserin?

There is no approved eplivanserin reference product for a conventional ANDA pathway. A sponsor would need to pursue an alternative regulatory strategy or develop a new application.

Does eplivanserin have value as a licensing asset?

Its value is speculative and primarily option-based. The main constraints are regulatory failure, uncertain current patent rights, and competition from approved insomnia treatments.

Could eplivanserin return to the market?

A return is theoretically possible but would require rights confirmation, renewed clinical development, FDA engagement, and successful demonstration of a benefit-risk profile that addresses the historical concerns.

References

  1. U.S. Food and Drug Administration. (2009). FDA briefing document: Eplivanserin for the treatment of insomnia. Center for Drug Evaluation and Research.

  2. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. FDA.

More… ↓

⤷  Start Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.